Results 11 to 20 of about 2,212 (184)

Expanding the Patient Pool for Rilonacept [PDF]

open access: yesJACC: Case Reports
Recurrent pericarditis complicates 15%-30% of acute pericarditis cases despite initial anti-inflammatory treatment. The RHAPSODY trial (Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis) showed ...
Emma St. John, MD   +9 more
doaj   +4 more sources

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS) [PDF]

open access: yesJournal of Inflammation Research, 2010
Justin Gillespie, Rebeccah Mathews, Michael F McDermottNIHR-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU), Leeds Institute of Molecular Medicine (LIMM), St.
Justin Gillespie   +2 more
doaj   +6 more sources

Recurrent Sterile Pleuropericarditis After Withdrawal of Renal Transplant Immunosuppression in Anuric ESRD: A Case of Suspected IL-1–Mediated Autoinflammation [PDF]

open access: yesCase Reports in Rheumatology
Recurrent pericarditis and serositis pose a significant diagnostic challenge in patients with end-stage renal disease (ESRD) and a history of extensive immunosuppression.
Evelien van Gelderen   +2 more
doaj   +3 more sources

Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis [PDF]

open access: yesCureus, 2022
Interleukin 1 (IL-1) has been indicated as a mediator of recurrent pericarditis. Rilonacept, a soluble IL-1 receptor chimeric fusion protein neutralizing interleukin 1 alpha (IL-1α) and interleukin 1 beta (IL-1β), has demonstrated promising results in a ...
Amen, Shwan   +12 more
core   +7 more sources

Mechanistic Insights and Emerging Therapeutic Strategies in Recurrent Pericarditis [PDF]

open access: yesMethodist DeBakey Cardiovascular Journal
Recurrent pericarditis is a heterogeneous and often debilitating inflammatory disorder characterized by recurrent flares following a symptom-free interval of at least 4 to 6 weeks.
Mohammad A. Alqahtani   +2 more
doaj   +2 more sources

Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome

open access: yesRMD Open, 2020
Objectives Several therapies are used for the treatment of rareautoinflammatory conditions like cryopyrin-associated periodic fever syndromes (CAPS), hyperimmunoglobulin Dsyndrome (HIDS)/mevalonate kinase deficiency (MKD) and tumour necrosis factor ...
Peter Hur   +5 more
doaj   +2 more sources

Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Recurrent pericarditis is an interleukin‐1–mediated chronic autoinflammatory disease. The phase 3 study RHAPSODY (Rilonacept Inhibition of IL‐1 Alpha and IL‐1 Beta for Recurrent Pericarditis: a Pivotal Symptomatology and Outcomes Study ...
Lucia Trotta   +11 more
doaj   +2 more sources

Interleukin-1 Blockade With Rilonacept in Recurrent Pericarditis: Tapering and Discontinuation in Real-World Practice. [PDF]

open access: yesJACC Adv
[Figure: see text]
Marchetta M   +9 more
europepmc   +3 more sources

Constrictive-effusive pericarditis as presenting feature of IgG4-related disease (IgG4-RD): a case report [PDF]

open access: yesJournal of Medical Case Reports
Background IgG4-Related Disease (IgG4-RD) is a fibroinflammatory disorder initially identified as autoimmune pancreatitis but subsequently shown in numerous other organs with common pathological hallmarks.
Robert Fekete
doaj   +2 more sources

Home - About - Disclaimer - Privacy